B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.

Ana Luisa StefanskiHector Rincon-ArevaloEva SchrezenmeierKirsten KarbergFranziska SzelinskiJacob RitterBernd JahrsdörferHubert SchrezenmeierCarolin LudwigArne SattlerKatja KotschYidan ChenAnne ClaußnitzerHildrun HaibelFabian ProftGabriela GuerraPawel DurekFrederik HeinrichMarta Ferreira-GomesGerd R BurmesterAndreas RadbruchMir-Farzin Mashreghi Andreia C LinoThomas Dörner

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2022)

In RTX-treated patients, a minimum of 10 B cells per microliter in the peripheral circulation is a candidate biomarker for a high likelihood of an appropriate cellular and humoral response after SARS-CoV-2 vaccination. Mechanistically, the data emphasize the crucial role of costimulatory B cell functions for the proper induction of CD4 responses propagating vaccine-specific B cell and plasma cell differentiation.

Keyphrases

sars cov
immune response
end stage renal disease
newly diagnosed
respiratory syndrome coronavirus
ejection fraction
chronic kidney disease
peritoneal dialysis
electronic health record
big data
data analysis
nk cells
chemotherapy induced